VAI-SU2C Epigenetics Dream Team

14 results.

October 12, 2017 Stand Up To Cancer awards $5.5 million to VARI for cancer clinical trials to enhance immunotherapy

GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team (VARI-SU2C) scientists have been awarded two…

May 15, 2017 Dr. Stephen Baylin becomes third VARI-affiliated scientist to be elected to National Academy of Sciences

VARI-affiliated cancer researcher Stephen Baylin, M.D., has been elected to the National Academy of Sciences…

March 7, 2017 New drug combination targets aggressive blood cancer

Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial

GRAND RAPIDS, Mich. (March 7,…

October 10, 2016 Combinations and collaborations in the fight against cancer: An interview with Dr. Feyruz Rassool and Dr. Stephen Baylin

What happens when scientists collaborate rather than compete? In this case, the result is a combination of two drugs that may be a more effective…

August 29, 2016 Vitamin C may boost effectiveness of acute myeloid leukemia treatment

EDITOR’S NOTE: Maintaining proper nutrition is an important part of cancer therapy. Patients are urged to consult their doctors before making any change to their…

October 20, 2014 Stand Up To Cancer Epigenetics Dream Team continues with $7.5 million funding from Van Andel Research Institute

Grand Rapids, Michigan (October 20, 2014)— The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus…